Xeris Biopharma (XERS) Q2 2026: Recorlev Fuels Top-Line Growth as Revenue Guidance Rises

Quarterly highlights: revenue growth in a focused portfolio

In the quarter ended June 30, 2026, Xeris reported total revenue of over $92 million, underscoring a robust top line driven by products under its portfolio. Net product revenue grew 34% year over year to just over $91 million, a sign that the company’s core commercial franchises are gaining traction. The standout contributor within product revenue was Recorlev, whose net revenue rose 81% year over year to approximately $57 million, highlighting strong demand and commercial momentum for the lead asset.

On a quarterly basis, Recorlev generated about $56.8 million in the three months ended June 30, 2026, compared with roughly $31.4 million in the prior-year period. The comparison underscores a meaningful acceleration in this asset’s contribution to the business, even as Xeris continues to support other products in its lineup.

Guidance: revenue forecast lifts the ceiling

Xeris tightened its full-year 2026 revenue forecast to a range of $385 million to $390 million. This update signals management’s confidence in continued momentum, particularly from Recorlev, and suggests the company expects the current growth trajectory to extend through year‑end. Investors will parse how this forecast aligns with operating expenses and whether the company can convert top-line strength into improved earnings per share (EPS), given that the release does not provide an EPS figure in this excerpt.

Pipeline optics: patent milestones and portfolio stability

A notable development is a Notice of Allowance from the United States Patent and Trademark Office for a new Keveyis patent, expected to extend intellectual property protection through at least 2039. The milestone reinforces strategic positioning for Keveyis within Xeris’ portfolio and provides a longer horizon of potential revenue contribution from a product with established commercial presence.

Company management emphasized that the commercial engine—driven by Recorlev, with continued support from Gvoke and Keveyis—remains central to the year’s narrative. The tone from leadership suggests a focus on deploying capital to accelerate growth within a lean profit framework, a dynamic that will matter to EPS consensus in the near term.

Management commentary: strategy, momentum, and the path ahead

“The second quarter was another strong period for Xeris, with net product revenue growing 34% year-over-year, driven by Recorlev’s exceptional commercial momentum,” said John Shannon, Chairman and Chief Executive Officer of Xeris. “The strategic investments we made for Recorlev earlier this year are gaining traction, and we expect their contribution to become increasingly meaningful as we move through the second half of 2026. Additionally, Gvoke delivered solid sequential improvement in line with our expectations, and Keveyis continued to provide a consistent, high-value contribution to our business.”

The commentary underscores a dual narrative: rapid growth from a marquee asset and stable support from legacy products. While the release highlights revenue, observers will be keen to see how operating expenses evolve and whether the company can translate this top-line strength into a more favorable earnings mix, potentially affecting EPS and the EPS consensus in the coming quarters.

Takeaways for XERS and peers: a lane-change moment for the sector?

The quarter reinforces a trend in which a single asset—Recorlev—can meaningfully shift a biotech’s revenue mix, especially when paired with a patent moat for a complementary product like Keveyis. For sector peers, the message is twofold: growth can be more durable when a company couples commercialization excellence with IP protection that extends beyond the near term. And while “EPS” remains a focus for investors, this release makes clear that revenue forecast discipline and portfolio optics can be a cleaner early signal of a company’s trajectory than a handful of headline quarterly earnings beats on the per-share line.

The balance of concentration risk (a few drivers of revenue) and portfolio resilience (Gvoke, Keveyis) will be scrutinized by analysts as the year advances. If Recorlev sustains its trajectory, the company may begin to show improving gross margins and operating leverage—an essential factor for reaching a more favorable EPS outcome and aligning with EPS consensus expectations.

Risks and nearest-term considerations

While the milestones are encouraging, several caveats remain. The press release emphasizes revenue growth but does not disclose EPS data for the current quarter, making it harder to gauge profitability in the near term. R&D spend, manufacturing costs, and potential competitive developments in the autoimmune/rare disease space could impact margin expansion. The patent milestone for Keveyis adds resilience, but long-run performance will depend on continued demand for each product category and the ability to sustain Recorlev’s momentum in a reimbursement and payer environment that remains sensitive to cost and coverage decisions.

Bottom line: what this portends

The Q2 release positions Xeris as a company with a more pronounced revenue engine centered on Recorlev, supported by a patent-protected Keveyis franchise and a steady Gvoke base. The tightened revenue forecast for 2026 suggests management confidence in sustaining growth into the second half of the year. For investors, the near-term questions will be: will EPS catch up to this revenue cadence, and how will the market price the durability of Recorlev’s growth against competitive and payer dynamics? If the answers tilt positive, EPS sentiment and the EPS consensus could begin to reflect a more favorable view of XERS’ profitability trajectory, even as the stock navigates the usual biotech volatility.